Global VISTA Inhibitor Clinical Trials & Market Opportunity Insight 2024
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Global VISTA Inhibitor Clinical Trials & Market Opportunity Insight 2024 Report Highlights:
V-domain Ig suppressor of T cell activation, commonly known as VISTA, is an immune checkpoint protein which exerts both inhibitory and stimulatory effects on the immune system. Other identified immune checkpoints are only known to negatively regulate immune responses, which is why the latter makes VISTA unique. Blocking its inhibitory functions has emerged as a hot approach in the treatment of cancer, while its immune system stimulatory functions have been explored widely in murine models.
With these research studies serving as the foundation, several pharmaceutical and biotechnology companies have been focusing on the development of therapeutic interventions that target the VISTA, mainly for the management of cancer, given that most clinical studies were conducted to elucidate its role in cancer. However, the field has not been without challenges, with many candidates being withdrawn from clinical development. However, new generation VISTA inhibitors are being developed to address the shortcomings of these candidates.
CA-170, developed by Aurigene Oncology and Curis, marks a significant advancement in the landscape of VISTA-targeted therapies. CA-170 is a first-in-class oral small molecule that directly targets both PD-1/PD-L1 and VISTA pathways. It is currently undergoing phase 2/3 clinical trials in India for the management of non-squamous non-small cell lung cancer, making it the candidate farthest ahead in the pipeline of VISTA-targeted therapies. While CA-170 has shown anti-tumor activity in multiple preclinical models, results from these ongoing clinical trials are yet to be revealed by Aurigene or Curis.
In addition to Aurigene and Curis, several research institutes, and biotechnology and pharmaceutical companies are actively pursuing VISTA inhibitors; these include Cancer Prevention and Research Institute of Texas, Kineta, Sensei Biotherapeutics, Washington University among others. Therefore, the current market for VISTA targeted therapies is witnessing a high level of competition and innovation, albeit with smaller companies dominating and larger companies waiting for breakthroughs before making their way into the market.
At present, cancer, mainly solid tumors, are dominating the research and development landscape of VISTA-targeted therapies. However, ongoing research has also associated the functions of VISTA with autoimmune and inflammatory disorders, wherein aberrant immune system activation damages tissue. This can however, with averted with the use of VISTA agonists, which can help expand the potential of VISTA as a therapeutic target to diseases mediated by the immune system. Additionally, modulation of VISTA activity has also been linked to viral infection through research findings indicating the VISTA plays a role in regulating the immune responses in viral infections. Therefore, as research findings continue linking VISTA functions to new indications, it becomes increasingly evident that researchers are yet to unravel the complexities of VISTA.
In conclusion, the landscape of VISTA-targeted therapeutics is characterized by active research, early-stage clinical development, and growing interest from both the scientific community and the pharmaceutical sector. As research progresses, VISTA inhibitors emerge as a beacon of innovation, holding up hope not only for cancer treatments but also for viral infections, autoimmune illnesses, and other ailments.
Global VISTA Inhibitor Clinical Trials & Market Opportunity Insight 2024 Report Highlights:
- Global VISTA Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase
- VISTA Inhibitors Clinical Trials: 8 Drugs
- US Dominating VISTA Inhibitors Clinical Trials Landscape: 5 Drugs
- Global VISTA Inhibitors Market Trends & Clinical Innovation
- Competitive Landscape: Insight On 10 Companies
- Future Clinical & Commercialization Opportunities
V-domain Ig suppressor of T cell activation, commonly known as VISTA, is an immune checkpoint protein which exerts both inhibitory and stimulatory effects on the immune system. Other identified immune checkpoints are only known to negatively regulate immune responses, which is why the latter makes VISTA unique. Blocking its inhibitory functions has emerged as a hot approach in the treatment of cancer, while its immune system stimulatory functions have been explored widely in murine models.
With these research studies serving as the foundation, several pharmaceutical and biotechnology companies have been focusing on the development of therapeutic interventions that target the VISTA, mainly for the management of cancer, given that most clinical studies were conducted to elucidate its role in cancer. However, the field has not been without challenges, with many candidates being withdrawn from clinical development. However, new generation VISTA inhibitors are being developed to address the shortcomings of these candidates.
CA-170, developed by Aurigene Oncology and Curis, marks a significant advancement in the landscape of VISTA-targeted therapies. CA-170 is a first-in-class oral small molecule that directly targets both PD-1/PD-L1 and VISTA pathways. It is currently undergoing phase 2/3 clinical trials in India for the management of non-squamous non-small cell lung cancer, making it the candidate farthest ahead in the pipeline of VISTA-targeted therapies. While CA-170 has shown anti-tumor activity in multiple preclinical models, results from these ongoing clinical trials are yet to be revealed by Aurigene or Curis.
In addition to Aurigene and Curis, several research institutes, and biotechnology and pharmaceutical companies are actively pursuing VISTA inhibitors; these include Cancer Prevention and Research Institute of Texas, Kineta, Sensei Biotherapeutics, Washington University among others. Therefore, the current market for VISTA targeted therapies is witnessing a high level of competition and innovation, albeit with smaller companies dominating and larger companies waiting for breakthroughs before making their way into the market.
At present, cancer, mainly solid tumors, are dominating the research and development landscape of VISTA-targeted therapies. However, ongoing research has also associated the functions of VISTA with autoimmune and inflammatory disorders, wherein aberrant immune system activation damages tissue. This can however, with averted with the use of VISTA agonists, which can help expand the potential of VISTA as a therapeutic target to diseases mediated by the immune system. Additionally, modulation of VISTA activity has also been linked to viral infection through research findings indicating the VISTA plays a role in regulating the immune responses in viral infections. Therefore, as research findings continue linking VISTA functions to new indications, it becomes increasingly evident that researchers are yet to unravel the complexities of VISTA.
In conclusion, the landscape of VISTA-targeted therapeutics is characterized by active research, early-stage clinical development, and growing interest from both the scientific community and the pharmaceutical sector. As research progresses, VISTA inhibitors emerge as a beacon of innovation, holding up hope not only for cancer treatments but also for viral infections, autoimmune illnesses, and other ailments.
1. VISTA: AN EMERGING IMMUNE CHECKPOINT
1.1 Introduction to VISTA Inhibition
1.2 Structure & Biology Of VISTA Protein
1.3 Mechanism of Action of VISTA Inhibitors
1.4 VISTA Inhibition v/s Conventional Immune Checkpoints Inhibitors
2. DUAL ROLE OF VISTA AS INHIBITORY & COSTIMULATORY CHECKPOINT
2.1 VISTA as Inhibitory Immune Checkpoint
2.2 VISTA as Costimulatory Checkpoint
3. SIGNIFICANCE OF VISTA
3.1 Role of VlSTA in Facilitating Cancer Progression
3.2 VISTA as Potential Cancer Biomarker
3.3 VISTA as Therapeutic Target in Autoimmunity
4. GLOBAL VISTA INHIBITORS MARKET TRENDS & CLINICAL INNOVATION
4.1 Current Market Scenario
4.2 Future Clinical & Commercialization Opportunities
5. VISTA TARGETED THERAPIES TRENDS & CLINICAL INNOVATION BY INDICATION
5.1 Lung Cancer
5.2 Bladder Cancer
5.3 Colorectal Cancer
5.4 Hematological Cancers
5.5 Autoimmune, Inflammatory, Microbial, & Allergic Disorders
6. VISTA TARGETED THERAPIES TRENDS & CLINICAL INNOVATION BY REGION
6.1 India
6.2 Australia
6.3 US
6.4 Europe
7. GLOBAL VISTA INHIBITORS CLINICAL TRIALS OVERVIEW
7.1 By Country
7.2 By Drug Class
7.3 By Indication
7.4 By Organization
7.5 By Phase
8. GLOBAL VISTA INHIBITORS CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE
8.1 Preclinical
8.2 Phase - I
8.3 Phase - I/II
8.4 Phase – III
9. GLOBAL VISTA INHIBITORS MARKET DYNAMICS
9.1 Market Drivers & Opportunities
9.2 Market Challenges & Restraints
10. COMPETITIVE LANDSCAPE
10.1 Adimab
10.2 Aurigene Discovery Technologies
10.3 Curis
10.4 Hummingbird Bioscience
10.5 Kineta
10.6 Korea Drug Development Fund
10.7 Merck
10.8 Pierre Fabre
10.9 PharmAbcine
10.10 Sensei Biotherapeutics
Figure 1-1: VISTA Protein - Structure
Figure 1-2: VISTA - Binding Partners
Figure 1-3: VISTA Inhibition - Basic Mechanism
Figure 1-4: VISTA Inhibition - Edge Over Conventional Checkpoint Inhibition
Figure 4-1: VISTA Inhibitors - Current Market Landscape
Figure 4-2: VISTA Inhibitor – Key Players
Figure 5-1: Pierre Fabre Laboratories - K01401-020 (W0180) Research Study
Figure 5-2: CA-170 - Clinical Trial Insights
Figure 5-3: HMBD-002 Phase I (NCT05082610) Study – Initiation & Completion Year
Figure 5-4: Lung Cancer VISTA Inhibitor – Clinical Landscape
Figure 5-5: Sensei Bio Collaborations
Figure 5-6: SNS-101 Phase I/II (NCT05864144) Study – Initiation & Completion Year
Figure 5-7: Sensei Bio Clinical Pipeline – VISTA Preclinical & Clinical Candidates
Figure 5-8: Cleveland Clinic Research Study for VISTA Inhibitors, May 2024
Figure 5-9: KVA12123 Phase I/II (NCT05708950) Study – Initiation & Completion Year
Figure 5-10: Kineta Q1 Financial Results
Figure 5-11: Aspects Influencing Global VISTA Hematological Market
Figure 5-12: Kings College London & Dartmouth College VISTA Patent
(US10745467B2) – Grant & Expiration Year
Figure 6-1: PMC-309 Phase 1 (NCT05957081) Study – Initiation & Completion Year
Figure 7-1: Global – Number Of VISTA Inhibitors In Clinical Trials By Country, 2024
Figure 7-2: Global – Number Of VISTA Inhibitors In Clinical Trials By Drug Class, 2024
Figure 7-3: Global – Number Of VISTA Inhibitors In Clinical Trials By Indication, 2024
Figure 7-4: Global – Number Of VISTA Inhibitors In Clinical Trials By Organization, 2024
Figure 7-5: Global – Number Of VISTA Inhibitors In Clinical Trials By Phase, 2024
Figure 9-1: Market Drivers & Opportunities
Figure 9-2: Market Challenges & Restraints
Table 5-1: Role of VISTA in Allergic, Autoimmune Disease & Viral Ailments
Table 6-1: US – Ongoing Clinical Trials for VISTA inhibitors
Table 10-1: Curis – VISTA Inhibitors Drugs Clinical Trials Insight
Table 10-2: Curis Merck & Co. – VISTA Inhibitors Drugs Clinical Trials Insight
Table 10-3: Sensei Biotherapeutics – VISTA Inhibitors Drugs Clinical Trials Insight
1.1 Introduction to VISTA Inhibition
1.2 Structure & Biology Of VISTA Protein
1.3 Mechanism of Action of VISTA Inhibitors
1.4 VISTA Inhibition v/s Conventional Immune Checkpoints Inhibitors
2. DUAL ROLE OF VISTA AS INHIBITORY & COSTIMULATORY CHECKPOINT
2.1 VISTA as Inhibitory Immune Checkpoint
2.2 VISTA as Costimulatory Checkpoint
3. SIGNIFICANCE OF VISTA
3.1 Role of VlSTA in Facilitating Cancer Progression
3.2 VISTA as Potential Cancer Biomarker
3.3 VISTA as Therapeutic Target in Autoimmunity
4. GLOBAL VISTA INHIBITORS MARKET TRENDS & CLINICAL INNOVATION
4.1 Current Market Scenario
4.2 Future Clinical & Commercialization Opportunities
5. VISTA TARGETED THERAPIES TRENDS & CLINICAL INNOVATION BY INDICATION
5.1 Lung Cancer
5.2 Bladder Cancer
5.3 Colorectal Cancer
5.4 Hematological Cancers
5.5 Autoimmune, Inflammatory, Microbial, & Allergic Disorders
6. VISTA TARGETED THERAPIES TRENDS & CLINICAL INNOVATION BY REGION
6.1 India
6.2 Australia
6.3 US
6.4 Europe
7. GLOBAL VISTA INHIBITORS CLINICAL TRIALS OVERVIEW
7.1 By Country
7.2 By Drug Class
7.3 By Indication
7.4 By Organization
7.5 By Phase
8. GLOBAL VISTA INHIBITORS CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE
8.1 Preclinical
8.2 Phase - I
8.3 Phase - I/II
8.4 Phase – III
9. GLOBAL VISTA INHIBITORS MARKET DYNAMICS
9.1 Market Drivers & Opportunities
9.2 Market Challenges & Restraints
10. COMPETITIVE LANDSCAPE
10.1 Adimab
10.2 Aurigene Discovery Technologies
10.3 Curis
10.4 Hummingbird Bioscience
10.5 Kineta
10.6 Korea Drug Development Fund
10.7 Merck
10.8 Pierre Fabre
10.9 PharmAbcine
10.10 Sensei Biotherapeutics
Figure 1-1: VISTA Protein - Structure
Figure 1-2: VISTA - Binding Partners
Figure 1-3: VISTA Inhibition - Basic Mechanism
Figure 1-4: VISTA Inhibition - Edge Over Conventional Checkpoint Inhibition
Figure 4-1: VISTA Inhibitors - Current Market Landscape
Figure 4-2: VISTA Inhibitor – Key Players
Figure 5-1: Pierre Fabre Laboratories - K01401-020 (W0180) Research Study
Figure 5-2: CA-170 - Clinical Trial Insights
Figure 5-3: HMBD-002 Phase I (NCT05082610) Study – Initiation & Completion Year
Figure 5-4: Lung Cancer VISTA Inhibitor – Clinical Landscape
Figure 5-5: Sensei Bio Collaborations
Figure 5-6: SNS-101 Phase I/II (NCT05864144) Study – Initiation & Completion Year
Figure 5-7: Sensei Bio Clinical Pipeline – VISTA Preclinical & Clinical Candidates
Figure 5-8: Cleveland Clinic Research Study for VISTA Inhibitors, May 2024
Figure 5-9: KVA12123 Phase I/II (NCT05708950) Study – Initiation & Completion Year
Figure 5-10: Kineta Q1 Financial Results
Figure 5-11: Aspects Influencing Global VISTA Hematological Market
Figure 5-12: Kings College London & Dartmouth College VISTA Patent
(US10745467B2) – Grant & Expiration Year
Figure 6-1: PMC-309 Phase 1 (NCT05957081) Study – Initiation & Completion Year
Figure 7-1: Global – Number Of VISTA Inhibitors In Clinical Trials By Country, 2024
Figure 7-2: Global – Number Of VISTA Inhibitors In Clinical Trials By Drug Class, 2024
Figure 7-3: Global – Number Of VISTA Inhibitors In Clinical Trials By Indication, 2024
Figure 7-4: Global – Number Of VISTA Inhibitors In Clinical Trials By Organization, 2024
Figure 7-5: Global – Number Of VISTA Inhibitors In Clinical Trials By Phase, 2024
Figure 9-1: Market Drivers & Opportunities
Figure 9-2: Market Challenges & Restraints
Table 5-1: Role of VISTA in Allergic, Autoimmune Disease & Viral Ailments
Table 6-1: US – Ongoing Clinical Trials for VISTA inhibitors
Table 10-1: Curis – VISTA Inhibitors Drugs Clinical Trials Insight
Table 10-2: Curis Merck & Co. – VISTA Inhibitors Drugs Clinical Trials Insight
Table 10-3: Sensei Biotherapeutics – VISTA Inhibitors Drugs Clinical Trials Insight
